Insider Selling: Cellebrite DI (NASDAQ:CLBT) CRO Sells 12,562 Shares of Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CRO Marcus Jewell sold 12,562 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.24, for a total transaction of $141,196.88. Following the completion of the transaction, the executive directly owned 427,128 shares of the company’s stock, valued at $4,800,918.72. This represents a 2.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Marcus Jewell also recently made the following trade(s):

• On Wednesday, August 12th, Marcus Jewell sold 411 shares of Cellebrite DI stock. The stock was sold at an average price of $16.07, for a total value of $6,604.77.

Cellebrite DI Price Performance

Shares of NASDAQ CLBT traded up $0.44 during mid-day trading on Monday, hitting $11.49. The company had a trading volume of 3,463,245 shares, compared to its average volume of 2,270,829. The company has a market capitalization of $2.87 billion, a PE ratio of 52.23, a price-to-earnings-growth ratio of 1.53 and a beta of 1.18. The business’s 50-day simple moving average is $14.27 and its 200 day simple moving average is $13.85. Cellebrite DI Ltd. has a 1-year low of $9.58 and a 1-year high of $19.98.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on CLBT shares. Lake Street Capital lowered their price objective on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Weiss Ratings downgraded shares of Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, August 13th. Needham & Company LLC dropped their price objective on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research report on Friday, August 14th. DA Davidson decreased their price objective on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Finally, JPMorgan Chase & Co. dropped their target price on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.70.

Institutional Trading of Cellebrite DI

Several institutional investors have recently modified their holdings of CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its holdings in Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares during the period. CWM LLC lifted its holdings in Cellebrite DI by 57.0% in the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after acquiring an additional 889 shares during the period. SkyView Investment Advisors LLC boosted its position in shares of Cellebrite DI by 2.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock worth $597,000 after purchasing an additional 970 shares in the last quarter. Alamea Verwaltungs GmbH grew its stake in shares of Cellebrite DI by 4.3% during the 4th quarter. Alamea Verwaltungs GmbH now owns 24,648 shares of the company’s stock worth $444,000 after purchasing an additional 1,018 shares during the period. Finally, Pacer Advisors Inc. grew its stake in shares of Cellebrite DI by 45.1% during the 4th quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock worth $72,000 after purchasing an additional 1,238 shares during the period. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.